Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer
Main Authors: | Yan Song, Yanni Hao, Alexander R. Macalalad, Peggy L. Lin, James E. Signorovitch, Eric Q. Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2015-09-01
|
Series: | Breast Cancer: Basic and Clinical Research |
Online Access: | http://www.la-press.com/clinical-outcomes-with-first-line-endocrine-therapy-or-chemotherapy-in-article-a5049 |
Similar Items
-
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer
by: Yan Song, et al.
Published: (2015-01-01) -
Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: a systematic review and meta-analysis
by: Ping Wu, et al.
Published: (2024-02-01) -
Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
by: Yang Yuan, et al.
Published: (2023-06-01) -
CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
by: Ni Zeng, et al.
Published: (2023-06-01) -
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
by: Mark Pegram, et al.
Published: (2023-08-01)